Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells by Mencía Rodríguez, Ángeles et al.
This document is published at:
Mencía A., Chamorro C., Bonafont J., Duarte B., Holguin A., Illera N., Llames, S.G., Escámez M.J., Hauser I., 
Del Río M., Larcher F., Murillas R. (2018). Deletion of a Pathogenic Mutation-Containing Exon of COL7A1 
Allows Clonal Gene Editing Correction of RDEB Patient Epidermal Stem Cells. Molecular Therapy Nucleic 
Acids, 11, pp. 68-78.
DOI: https://doi.org/10.1016/j.omtn.2018.01.009
Funding entities: FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de investigación 
SAF2017-86810-R y SAF2013-43475-R
© 2018 The Authors
This  work  is  licensed  under  a  Creative Commons  Attribution-NonCommercial-NoDerivatives  4.0 
International License.
Original ArticleDeletion of a Pathogenic Mutation-Containing
Exon of COL7A1 Allows Clonal Gene Editing
Correction of RDEB Patient Epidermal Stem Cells
Ángeles Mencía,1,4,5,6 Cristina Chamorro,2,4,5,6 Jose Bonafont,2,4 Blanca Duarte,1,4,5 Almudena Holguin,1,4,5
Nuria Illera,1,4,5 Sara G. Llames,5 Maria José Escámez,2,4,5 Ingrid Hausser,3 Marcela Del Río,1,2,4,5
Fernando Larcher,1,2,4,5 and Rodolfo Murillas1,4,5
1Epithelial Biomedicine Division, Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain; 2Department of Biomedical
Engineering, Carlos III University (UC3M), Madrid, Spain; 3Institute of Pathology, Universitätsklinikum Heidelberg, Heidelberg, Germany; 4Instituto de Investigación
Sanitaria de la Fundación Jiménez Díaz, Madrid, Spain; 5Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER) U714, Madrid, SpainReceived 22 December 2017; accepted 23 January 2018;
https://doi.org/10.1016/j.omtn.2018.01.009.
6These authors contributed equally to this work.
Correspondence: Rodolfo Murillas, PhD, Epithelial Biomedicine Division, Cuta-
neous Disease Modeling Unit, CIEMAT-CIBERER (Centre for Biomedical
Research on Rare Diseases) U714, Avenida Complutense 40, Madrid 28040, Spain.
E-mail: rodolfo.murillas@ciemat.es
Correspondence: Fernando Larcher, PhD, Epithelial Biomedicine Division,
Cutaneous Disease Modeling Unit, CIEMAT-CIBERER (Centre for Biomedical
Research on Rare Diseases) U714, Avenida Complutense 40, Madrid 28040, Spain.
E-mail: fernando.larcher@ciemat.esRecessive dystrophic epidermolysis bullosa is a severe skin
fragility disease caused by loss of functional type VII collagen
at the dermal-epidermal junction. A frameshift mutation in
exon 80 of COL7A1 gene, c.6527insC, is highly prevalent in
the Spanish patient population. We have implemented gene-
editing strategies for COL7A1 frame restoration by NHEJ-
induced indels in epidermal stem cells from patients carrying
this mutation. TALEN nucleases designed to cut within the
COL7A1 exon 80 sequence were delivered to primary patient
keratinocyte cultures by non-integrating viral vectors. After
genotyping a large collection of vector-transduced patient ker-
atinocyte clones with high proliferative potential, we identiﬁed
a signiﬁcant percentage of clones with COL7A1 reading frame
recovery and Collagen VII protein expression. Skin equivalents
generated with cells from a clone lacking exon 80 entirely were
able to regenerate phenotypically normal human skin upon
their grafting onto immunodeﬁcient mice. These patient-
derived human skin grafts showed Collagen VII deposition
at the basement membrane zone, formation of anchoring
ﬁbrils, and structural integrity when analyzed 12 weeks after
grafting. Our data provide a proof-of-principle for recessive
dystrophic epidermolysis bullosa treatment through ex vivo
gene editing based on removal of pathogenic mutation-
containing, functionally expendable COL7A1 exons in patient
epidermal stem cells.
INTRODUCTION
Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin
fragility disease caused by loss-of-function mutations in COL7A1, a
gene expressed by keratinocytes and ﬁbroblasts that encodes type
VII collagen (C7), the main constituent of the anchoring ﬁbrils neces-
sary for adhesive connection between the dermis and the epidermal
basement membrane zone (BMZ). C7 deﬁciency results in severe
and recurrent blistering of the skin and other stratiﬁed epithelia,
scarring, and highly increased risk for development of metastatic
squamous cell carcinoma.1 Ex vivo gene therapy strategies for
epidermolysis bullosa, including junctional epidermolysis bullosa68 Molecular Therapy: Nucleic Acids Vol. 11 June 2018 ª 2018 The Au
This is an open access article under the CC BY-NC-ND license (http:and RDEB, based on transplantation of retroviral vector-modiﬁed
keratinocyte sheets are already in a clinical stage with promising
results.2–5 Also, an approach using graftable bioengineered skin equiv-
alents containing RDEB ﬁbroblasts and keratinocytes corrected by
means of a SIN-retroviral vector will soon be tested in patients.6 How-
ever, although gene addition tackles the wide range of disease-causing
mutations, retroviral vector-based gene transfer poses biosafety
concerns including inaccurate spatial-temporal gene expression and
potential genotoxicity risks.Moreover, the efﬁcacy of retroviral vectors
for the long-term correction of autologous skin grafts is not clearly
established yet.4 Thus, gene therapy protocols for monogenic disease
correction are moving from retroviral vector-based gene replacement
to more precise gene-editing approaches for highly speciﬁc interven-
tions on the defective gene at DNA and RNA levels.
Experimental demonstrations of gene-editing approaches for RDEB
therapy have included protocols based on patient-derived induced
pluripotent stem cells (iPSCs)7–9 and direct correction of patient
keratinocytes ex vivo by homology-directed repair (HDR)10–12 and
non-homologous end joining (NHEJ) strategies.11 “Skipping” of
pathogenic mutation-containing exons has been proven an efﬁcient
strategy for the correction of hereditary diseases caused by mutations
in genes coding for proteins with long, repetitive structural domains.
The best-characterized case and proof of principle for exon-skipping
therapy is dystrophin gene reading frame recovery by modulation of
its pre-mRNA splicing with synthetic antisense oligonucleotidesthors.
//creativecommons.org/licenses/by-nc-nd/4.0/).
www.moleculartherapy.org(AON) in Duchenne muscular dystrophy (DMD) muscle cells. Trun-
cated dystrophin proteins lacking the sequence encoded by the skip-
ped mutation-containing exons are partially functional, thus having
the potential to shift the phenotype from severe to mild.13 A similar
AON-based exon-skipping approach has been recently described for
recessive RDEB.14–17 COL7A1 is especially amenable to exon-skipping
correction strategies since all exons encoding the triple-helix forming
region, essential for the structural function of C7, are small, in frame,
and encode Gly-X-Y repeats. The functionality of internally deleted
Collagen VII variants lacking sequences encoded by speciﬁc collage-
nous domain exons has been demonstrated.15,17 However, despite
advances to increase their stability and the feasibility of in vivo appli-
cations, AONs can only promote transient masking of splicing motifs
and therefore allow for temporary correction of the genetic defect.
Permanent exon-skipping-mediated gene repair can be achieved by
introducing changes in theDNA sequence to eliminate intron-splicing
motifs or exonic sequences all together. Highly speciﬁc programmable
nucleases are able to generate DNA double-strand breaks in the prox-
imity of the pathogenic mutation sequence that are resolved by the
NHEJ DNA repair system, frequently leading to the introduction of
insertion and deletion (indel) mutations. This NHEJ-mediated strat-
egy was originally implemented for the ex vivo correction of DMD
patient muscular cells18,19 and later demonstrated by our laboratory
for the successful correction of RDEB patient-derived keratinocytes.11
It has also proved feasible for the in vivo correction of DMD20–22 and
RDEB in experimental mouse models when CRISPR/Cas9 were
delivered by AAV vectors or as RNP particles.23
Stringent biosafety standards, a necessary requirement for the imple-
mentation of gene therapy protocols, can be conceived by performing
accurate genotyping and genomic characterization of gene-modiﬁed
single epidermal stem cell clones with the potential to regenerate
gene-corrected skin.24–26 The feasibility of clonal-based therapy
with gene-targeted epidermal stem cells has been previously estab-
lished by our laboratory with the demonstration that long-term
skin regeneration from a human epidermal stem cell clone carrying
a targeted integration of a marker gene at the AAVS1 locus can be
attained.25,26 However, although studies in immortalized RDEB
keratinocytes showed the feasibility of the approach,11,12 clonal
therapy for RDEB based on isolation of epidermal stem cells modiﬁed
by gene-editing protocols to re-establish production of functional C7
has not yet been achieved.
With the aim of developing a gene-editing-based therapy speciﬁcally
tailored to the c.6527insC mutation in exon 80 of the COL7A1
gene,27 highly prevalent in the Spanish RDEB patient population,28
we have previously delivered TALEN nucleases by adenoviral vectors
able to introduce small deletions in the exon 80 of COL7A1 gene that
resulted in exon 80 skipping.11 Using these tools, and after thorough
analysis of a large collection of RDEB patient keratinocyte clones,
we have now achieved long-term skin regeneration from several
NHEJ-mediated COL7A1 gene frame-restored clones, including a
single epidermal stem cell clone with permanent exon deletion-based
RDEB correction.RESULTS
Transduction of Primary RDEB Keratinocytes with Ad-Talens
and Isolation and Genotyping of Keratinocyte Clones Carrying
Corrective Indels in COL7A1 Exon 80
Primary keratinocytes from RDEB patients previously character-
ized as homozygous carriers for the highly prevalent c.6527insC
COL7A1 mutation28 were infected with adenoviral vectors for the
expression of TALEN nucleases T6/T7,11 speciﬁc for COL7A1
exon 80 (Figure 1A). Different MOIs were assessed to establish
the optimal conditions for indel generation in primary RDEB
keratinocytes, as determined by Cel I analysis. A MOI of 300
was the lowest to yield high indel generation (Figure 1B) without
noticeable reduction in cell viability. Cells from two different
patients (P1 and P2) infected at optimized conditions, were split
at low density to isolate individual clones. Genotyping of clones
was performed by sequencing a PCR amplicon spanning the
nuclease target site. In the ﬁrst experiment using cells from P1,
22 keratinocyte clones were isolated and genotyped, two of which
(clones 11 and 40) carried a 1-nucleotide (guanine) deletion allele,
c.6512delG (named as DG) at the TALENs target site, correspond-
ing to the most frequent deletion detected in our previous editing
experiments with immortalized RDEB keratinocytes11 using the
same TALEN nucleases pair (experiment 1, Figure 1C). The other
20 clones in this experiment were unmodiﬁed, presenting the
c.6527insC allele sequence. Previously, we showed that the DG
deletion resulted in a frameshift leading to frame restoration
in c.6527insC COL7A1 mutation-bearing RDEB keratinocytes,
causing the expression of a variant transcript encoding a four-
amino-acid substitution in C7.11 Transcripts encoding this C7
variant were also found in P1 clones 11 and 40 when COL7A1
expression was analyzed by sequencing RT-PCR products span-
ning exons 78 to 84 (Figures S1A and S1B).
When the experiment was repeated using cells from P2, a larger
collection of keratinocyte clones were isolated and expanded, which
allowed us to screen a broader spectrum of indels. In this experiment,
14 out of 125 clones analyzed carried indels and the DG 1-bp deletion
was again the most commonly found (eight clones). In addition, one
clone with a different frame-restoring 1-bp deletion, four clones
carrying non-correcting mutations, and one clone (clone 19) with a
114-bp deletion entirely encompassing exon 80 were identiﬁed
(experiment 2, Figure 1C). All the other clones were unmodiﬁed
c.6527insC homozygous carriers.
Analysis of the sequence chromatograms of PCR products span-
ning the TALEN target site revealed that clone 11 carried one
DG deletion allele, while clone 40 was biallelically modiﬁed for
this mutation (Figure 2A). A careful analysis of the chromatogram
for clone 19 revealed multiple overlapping traces corresponding to
different COL7A1 alleles. Therefore, the PCR product for clone 19
was TA-cloned, and individual colonies were sequenced, revealing
the presence of three alleles: c.6527insC (pathogenic mutation, un-
edited), c.6502-39_6537+46del113 (114-bp deletion, encompassing
exon 80 entirely), and c.6503_6511del9 (9-bp deletion) (Figure 2B).Molecular Therapy: Nucleic Acids Vol. 11 June 2018 69
???????
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg
?????? ?????????????????
????????????????????????????????
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ????????
?????? ?????????????????
???????????????????????????????????????????? ???? ??????? ???
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ????????
?? ?????????????????? ??
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
?? ???????????????????????? ??
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
?? ??????????????????? ????? ??
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
?? ??????????????????????????? ??
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
??? ???????????????????????? ?
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
?? ??????????????????????????
gtgagg//tatgtag?????????????????????????????????????gtgagta//atcctg ???????
???? ??????????????????????????????? ??
gtg------------?????????????????????????????????????------------ctg ???????
A 
B 
C 
Figure 1. Indel Generation with TALEN Nucleases in
Primary RDEB Patient Keratinocytes
(A) TALEN pair T6/T7 targets the 50 region of the COL7A1
exon 80 sequence (upper case) in the vicinity of the
c.6527insC mutation (red arrowhead). TALEN spacer
sequence is shaded. Intron sequences are in blue lower case.
(B) The PCR product comprising the T6/T7 target site was
analyzed with Surveyor (Cel I) mutation detection assay to
establish optimal MOI in patient keratinocytes infected with
adenoviral vectors for T6/T7 TALEN expression. Solid
arrowhead indicates uncleaved DNA; arrowheads indicate
cleavage fragments. Percentage of cleavage for each PCR
product is shown at the bottom. M is IX molecular weight
marker. (C) Indel spectrum in keratinocytes from RDEB
patients 1 (experiment 1) and 2 (experiment 2) transduced
with Ad-T6/T7 vectors. Two out 22 clones in experiment 1
and 14 out of 125 clones in experiment 2 carried indel alleles
at the TALEN target site. The number of clones containing
each indel is shown on the right. Intron sequences are in
blue lowercase letters. Double slash marks represent DNA
sequences that are not shown.
Molecular Therapy: Nucleic AcidsThe 9-bp deletion found in the c.6503_6511del9 allele was
within the exon 80 sequence and not consistent with COL7A1
frame restoration. Immunoﬂuorescence analysis of DG deletion-
carrying clones 11 and 40 using an anti-human C7 monospeciﬁc
polyclonal antibody17 showed strong and homogeneous C7
staining (Figure 2C, upper panels). In contrast, and consistent
with the presence of three different COL7A1 alleles, immunoﬂuo-
rescence analysis of clone 19 revealed the presence of C7-positive
and -negative cells (Figure 2C, lower right panel) in similar pro-
portions, indicating that this clone may be comprised of a bi-clonal
population. A clone from experiment 2 that did not contain any
indels (clone 31) was used as a negative staining control (Figure 2C,
lower left panel).70 Molecular Therapy: Nucleic Acids Vol. 11 June 2018Isolation and Characterization of Pure Clones
from Clone 19 Mixed Population
To isolate pure keratinocyte clones carrying the
exon 80-excising 114-bp deletion allele, limiting
dilution subculture of the clone 19 mixed pop-
ulation was performed. C7 immunoﬂuorescence
analysis showed that, in contrast to the mixed
C7-positive and -negative pattern found in
parental clone 19 mixed population, all cells in
each keratinocyte subclone were either completely
positive or negative for C7 staining. Two C7-
expressing clones with proliferative potential,
named as 19.3 and 19.C, and one C7-negative
clone, named as 19n, were expanded for further
experimentation (Figure 3A). PCR analysis with
primers spanning the 114-bp deletion revealed
that, for clones 19.3 and 19.C, the higher and lower
molecular weight bands, whose mobility corre-
sponds to the undeleted (Figure 3A, black arrow-
head) and deleted (Figure 3A, red arrowhead)alleles, respectively, were of comparable intensity, unlike in
the parental clone 19. For the C7-negative clone 19n, only the
higher-molecular-weight band was detected (Figure 3B). The inter-
mediate molecular weight band detected in all C7-expressing clones
(19, 19.3, and 19.C) most likely corresponds to heteroduplex DNA
formation between deleted and undeleted alleles, as previously
reported for PCR genotyping of cells carrying deletion alleles in other
genes.29,30 Furthermore, the Sanger sequencing chromatogram of
PCR products for clones 19.3 and 19.C showed overlapping traces
corresponding exclusively to c.6527insC (unmodiﬁed) and c.6502-
39_c.6537+46del113 (114-bp deletion, DE80) alleles. These PCR
products were cloned in a plasmid vector, and individual colonies
were sequenced to unequivocally verify the presence of both alleles
Figure 2. Genotypes of RDEB Patient Keratinocyte
Clones Carrying Different Frame-Restoring Indels and
Collagen VII Expression Analysis
(A) Sanger sequencing chromatograms of PCR products
spanning the TALEN target site show the 1-bp DG deletion in
oneCOL7A1 allele (clone 11, upper chromatogram) or in both
(clone 40, lower chromatogram). The exon 80 sequence is
shown in the red box. (B) Chromatograms corresponding to
individual colonies of the TA-cloned PCR product for clone 19
showed three different alleles: unedited (upper), 9-bp deletion
(D9, middle), and 114-bp deletion (D114, lower). (C) Immu-
noﬂuorescence staining with anti-C7 antibody showed C7
expression in approximately half of the cells in clone 19 and in
all cells from clones 11 and 40.
www.moleculartherapy.org(Figure 3C). The c.6503_6511del9 (9-bp deletion) allele was not
found in these clones, showing that this allele was present in the
cellular subpopulation that was segregated from clones 19.3 and
19.C by subcloning. Consistently, genotyping of C7-negative clone
19n revealed the presence of overlapping chromatograms for the
c.6527insC (unmodiﬁed) and c.6503_6511del9 (9-bp deletion) alleles
in these cells (Figure S2).
To assess the speciﬁcity of TALENs activity, we identiﬁed genomic
sites with the potential for off-target cleavage by using the PROGNOS
software that ranks sites according to number of mismatches relative
to the intended target sequence and repeat variable diresidue (RVD)-
nucleotide binding frequencies.31 The presence of indel mutations
was assessed by performing Cel I analysis of PCR products containingMolecthese putative off-target cleavage sites, ampliﬁed
from genomic DNA of clones containing the
114-bp exon 80 deletion (19, 19.3, and 19.C). Thir-
teen of the highest scoring off-target sites, located
in loci different to COL7A1 gene were analyzed.
In addition, seven lower-scoring sites located
within the COL7A1 gene were scrutinized (Table
S1) because of the potential detrimental effect of
mutations introduced at these sites on our gene
repair strategy. No nuclease off-target cleavage
activity was detected in this analysis (Figure S3).
Since the 114-bp deletion completely eliminates the
exon 80 of COL7A1 gene, expression analyses were
performed in mixed clone 19 and subclones 19.3
and 19.C to study the presence of gene transcripts
lacking the exon 80-encoded sequence and there-
fore with restored open reading frame. RT-PCR
analysis of RNA samples from clones 19, 19.3,
and 19.C produced bands with a molecular weight
corresponding to the unedited (Figure 4A, black
arrowhead) and exon 80-deleted (red arrowhead)
alleles. In pure clones, 19.3, and 19.C, the smaller
molecular weight band corresponding to a short-
ened, frame-restored transcript lacking the exon80 sequence was more intense than the higher molecular weight
band corresponding to the out-of-frame transcript generated from
the unedited allele, which might be due to increased stability of the
exon 80-deleted transcript. To verify that the 114-bp deletion resulted
in splicing of COL7A1 pre-mRNA such that exons 79 and 81 are
joined together, the PCR products were TA-cloned and sequenced,
revealing transcripts lacking the exon 80-encoded sequence (Fig-
ure 4B) in clones 19, 19.3, and 19.C. Transcripts containing the
c.6527insC mutation encoded in the unedited allele were also found
for all three clones. In addition, transcripts originating from the
9-bp deletion allele, which was not conducive to frame restoration,
were found in mixed clone 19, but not in 19.3 and 19.C clones. To
quantify the expression of edited and unedited alleles in these clones,
quantitative real-time qPCR was performed using two probes, oneular Therapy: Nucleic Acids Vol. 11 June 2018 71
Figure 3. Isolation and Characterization of Pure Clones
from Clone 19 Mixed Population
(A) C7 immunoﬂuorescence analysis of subclones 19n, 19.3,
and 19.C obtained by limiting dilution subculture of clone 19
mixed population. Scale bar, 20 mm. (B) PCR analysis for the
detection of the 114-bp deletion in clone 19 and corre-
sponding subclones 19.3, 19.C, and 19n. Undeleted (black
arrowhead) and deleted (red arrowhead) alleles could be
detected using primers spanning the deletion region.
P2 genomic DNA from patient 2 keratinocytes was used as a
control for ampliﬁcation of the unedited allele. (), negative
control without DNA; M, IX molecular weight marker.
(C) Sanger sequencing of TA-cloned PCR products demon-
strated the presence of exclusively the unedited (upper chro-
matogram) and 114-bp deletion (D114, lower chromatogram)
alleles in clones 19.3 and 19.C. Exon 80 sequence shown in
red box. Black lines depict deletion boundaries.
Molecular Therapy: Nucleic Acidsrecognizing the COL7A1 exon 64 sequence (probe Ex64) and there-
fore detecting transcripts produced by both the edited and unedited
alleles and other recognizing the exon 80 sequence that will detect
only transcription from the unedited, exon 80 sequence-containing
allele (probe Ex80). For all three clones, COL7A1 expression was
higher with Ex64 probe than with Ex80 probe, proving that most of
COL7A1 transcription in these gene-edited clones originates from
the edited allele lacking the exon 80 sequence (Figure 4C).
C7 protein expression in keratinocyte clones was analyzed by western
blotting (WB) using an anti-human C7 monospeciﬁc polyclonal anti-
body.17 The amount of C7 in gene-edited clones was comparable to
that found in an unaffected patient sibling heterozygous for the null
mutation (P2s) and somewhat lower than in normal human keratino-
cytes (Figure 4D). Interestingly, higher C7 expression was found in
gene-edited clone 61, isolated in the experiment with patient P2 cells
and carrying the DG, 1-bp deletion allele that results in COL7A172 Molecular Therapy: Nucleic Acids Vol. 11 June 2018frame restoration but causes a predicted four-
amino-acid change (i.e., Gly-Pro-Arg-Gly to Val-
Gln-Glu-Ala), disrupting the Gly-X-Y pattern
characteristic of the triple helix forming domain.11
Similarly, increased amounts of C7, compared to
normal human keratinocytes, were found in clones
11 (monoallelic for DG deletion) and 40 (biallelic
for DG deletion), isolated in the experiment with
patient P1 cells, by western blot (Figure S1C).
Increased C7 might be explained by intracellular
retention of the protein due to hindered secretion
caused by defective triple-helix formation.
In Vivo Skin Regeneration with Frame-
Restored Clones: C7 Deposition and
Functional Analysis
To evaluate the functional effect of C7 expression
recovery either by COL7A1 frame restoration by
a 1-bp deletion that resulted in a four-amino-acid
substitution (clones 11 and 40) (Figure 5A) orexon 80 deletion (clones 19 and 19.C) (Figure 6A), skin equivalents
prepared with keratinocytes from the different clones, and C7 null
ﬁbroblasts were grafted onto immunodeﬁcient mice. The dermal-
epidermal adhesion phenotype and C7 deposition at the BMZ was
analyzed 12 weeks after grafting, a time point indicative of long-
term skin regeneration. Skin engraftment occurred for the four clones
and, macroscopically, the regenerated skin appeared normal (Figures
5B, 5C, and 6B). However, grafts from clones 11 and 40 showed
marked fragility as epidermis was easily separated from the dermis
upon mild pulling from the edge of an incision performed on the en-
grafted human skin using a scalpel (Figures 5D–5E; Figure S4). On the
contrary, skin regenerated from both mixed clone 19 and clone 19.C
showed mechanical resistance to the pulling test (Figure 6C). Immu-
noﬂuorescence analysis clearly showed C7 expression in grafts from
all clones. Interestingly, in grafts from clones 11 (Figure 5F) and 40
(Figure 5G), C7 was not at the BMZ, the physiological location
of this protein in skin grafts from normal human keratinocytes
Figure 4. COL7A1 Gene Expression Analysis in Frame-
Restored Clones
(A) RT-PCR analysis for detection of COL7A1 transcripts using
primers in exons 78 to 84. A 240/241-bp band (black
arrowhead) corresponding to wild-type/c.6527insC unedited
transcripts was ampliﬁed from all RNA samples (left). In addi-
tion, a 205-bp band (red arrowhead) corresponding to exon
80-lacking transcripts was found in clones 19, 19.3, and
19.C. M, IX molecular weight marker; HK, healthy human
keratinocytes; P2, patient keratinocytes; P2s, healthy hetero-
zygous patient sibling; (), negative control without cDNA.
GAPDH expression was analyzed as a loading control (right).
(B) TA-cloned RT-PCR products from clones 19, 19.3, and
19.C revealed the presence of transcripts originating from
the unedited pathogenic allele (upper chromatogram) and
transcripts lacking the exon 80-encoded sequence (lower
chromatogram). Black lines depict exon boundaries. Chro-
matograms corresponding to clone 19.C are shown. (C) Real-
time qPCRquantiﬁcation ofCOL7A1 expression using Taqman
probes speciﬁc for all COL7A1 transcripts (Ex64) and exon 80-
containing transcripts (Ex80). (D) Western blot analysis of C7
expression. P2, patient 2 keratinocytes; 19, 19.3, 19.C, clones
from P2 carrying the 114-bp deletion allele; 61, clone from P2
carrying theDG 1-bp deletion allele; P2s, healthy heterozygous
sibling keratinocytes; HK, healthy human keratinocytes.
www.moleculartherapy.org(Figure 5H), but it was instead retained within the cytoplasm of basal
keratinocytes, indicating a faulty secretion of the C7 variant produced
by these cells. In contrast, grafts from clones 19 and 19.C, showed cor-
rect C7 deposition at the BMZ zone (Figure 6F) with the same pattern
as in grafts generated from normal human keratinocytes (Figure 6G).
No C7 staining was found in grafts from unedited patient keratino-
cytes used as negative controls (Figures 5I and 6H). Blistering was
evident in grafts from clones 11 and 40 and in the control graft
from unedited patient keratinocytes (Figure 5F, 5G and 5I, asterisks).
Grafts generated from the mixed clone 19 showed the presence of C7
negative patches likely corresponding to the cells carrying the non-
correcting 9-bp deletion and matching blistering foci (Figure S5).
Epidermal-dermal adhesion and normal epidermal architecture of
human skin grafts generated with gene-corrected patient keratinocytes
fromclone19.Cwasveriﬁedbyhistological analysis (Figure 6D). Immu-
nohistochemical staining using an antibody speciﬁc for human involu-
crin showed normal human epidermal differentiation in the skin graft
(Figure 6E). Furthermore, ultrastructural analysis of grafts from clone
19.C showed the presence of mature anchoring ﬁbrils (Figure 6I,Molecarrowheads), demonstrating that not only is the C7
protein lacking exon 80-encoded sequence properly
produced and secreted but it is also ﬁt for anchoring
ﬁbril formation.
DISCUSSION
To achieve the generation of persistent genetically
corrected skin grafts with therapeutic potential,
targeting epidermal stem cells is necessary. Our
laboratory ﬁrst demonstrated the feasibility oflong-term skin regeneration from a single gene-targeted epidermal
stem cell clone.25 Here, we have achieved the ex vivo correction
of a genodermatosis by gene editing in patient epidermal stem
cells. Previous experimental approaches by our laboratory11 and
others7,10,12 had delineated protocols for recovery of C7 production
in RDEB patient-derived keratinocytes using gene editing strategies.
However, since studies based on selection of corrected clones have
been performed either on immortalized keratinocyte cell lines,11,12
patient-derived iPSC lines7 or polyclonal populations without
proven regenerative potential,10 they are still far from having clinical
relevance. Moreover, most reported studies have relied on the use of
drug selection to achieve correction by still highly inefﬁcient
HDR-based protocols.12 We recently established drug-selection-
free, NHEJ-based exon skipping strategies for highly efﬁcient recov-
ery of C7 expression in RDEB-derived keratinocytes.11 Building
upon this foundation, we have generated human skin from a single
RDEB patient epidermal stem cell with normal dermal-epidermal
adhesion features after recovering the expression of a functional
C7 protein variant, lacking the exon 80-encoded fragment, from
the endogenous mutant COL7A1 gene. Although this protocol hasular Therapy: Nucleic Acids Vol. 11 June 2018 73
Figure 5. In Vivo Skin Regeneration from Frame-Restored Patient
Keratinocyte Clones 11 and 40 Expressing a C7 Variant with a Four-Amino-
Acid Substitution
(A) COL7A1 cDNA and C7 amino acid sequences for WT, c.6527insC (cytosine
insertion underlined in red), and DG (1-bp deletion, red arrowhead) alleles. Amino
acid substitutions in c.6527insC and DG variants are shown in red. (B and C)
Macroscopic appearance of human skin (delineated by dotted line) regenerated
from clones 11 (B) and 40 (C). (D and E) Dermal-epidermal adhesion test.
Detachment of epidermis (blue arrows) occurred after pulling from the edge of
an incision on human skin grafts generated from clones 11 (D) and 40 (E). (F, G, H,
and I) Immunoﬂuorescence staining for the detection of human C7 (green) in grafts
sections. In grafts from clones 11 (F) and 40 (G), C7 was retained within the cyto-
plasm of keratinocytes in the basal layer of epidermis. In contrast, grafts from normal
human keratinocytes display C7 deposition in the BMZ (H). Grafts from unedited
patient 2 keratinocytes were used as a negative control for staining (I). Cell nuclei
were stained with DAPI (blue). Asterisks denote blisters formed between dermis and
epidermis (F, G, and I). Scale bar, 50 mm.
Molecular Therapy: Nucleic Acidsbeen developed for RDEB cells harboring a frameshift mutation in
exon 80 of the COL7A1 gene, highly prevalent in the Spanish and
Latin American RDEB patient population,28,32 the same strategy74 Molecular Therapy: Nucleic Acids Vol. 11 June 2018can be redeployed for mutations in other exons within COL7A1
collagenous domain. In fact, in vitro translated C7 protein lacking
the exon 105-encoded fragment conserved functionality in
biochemical assays and promoted skin stability when injected in
DEB mice.17 Likewise, RDEB patient keratinocytes transduced
with retroviral vectors for expression of C7 variants lacking exons
73- and 80-encoded fragments secreted C7 homotrimers, and skin
equivalents generated with these cells displayed restored C7 expres-
sion and dermal-epidermal adhesion.15 Although we have made use
of previously established TALEN nucleases to facilitate locus-
speciﬁc gene editing in our protocol, novel CRISPR/Cas9-based pro-
tocols will probably render remarkably increased editing efﬁciencies.
This might permit working with polyclonal populations of corrected
keratinocytes including gene-edited epidermal stem cells, which
would be advantageous for the generation of clinically useful skin
grafts. Still, monoclonal cellular therapy affords added beneﬁts
such as precise genotyping and biosafety characterization of individ-
ual clones24,26 prior to their use for generation of skin grafts, as
shown here.
However, challenging the proliferative capabilities of individual
epidermal stem cells to generate monoclonal grafts adds signiﬁcant
complexity to preclinical protocols. To circumvent this limitation,
we have resorted to adding a small molecule inhibitor of Rho-associ-
ated kinase (Y-27632) to our keratinocyte cell culture medium, which
greatly facilitates isolation and expansion of keratinocyte clones with
stem cell features.33 Although we are aware that the use of this reagent
in clinical settings might raise some regulatory concerns, the kerati-
nocyte stem cell clones isolated and characterized with our protocol
did not display any sign of morphological transformation and
rendered histologically normal skin grafts.
Under these conditions, we were able to isolate and expand over
100 clones, of which 8% showed expression of C7 variants, a pro-
portion similar to that previously found with the immortalized cell
line.11 All clones selected for grafting (i.e., clones 11, 40 carrying a
faulty COL7A1 frame-restoring indel, and the biclonal population
19, carrying a COL7A1 exon 80-deleted allele) showed engraftment
and persistence in vivo. Moreover, upon subcloning to obtain a
monoclonal population with an exon 80-deleted variant (i.e., Clone
19.C), long-term skin regeneration was also achieved. Although
different C7 variants can be produced by NHEJ repair leading to
COL7A1 frame restoration, not all of them produce functional
C7 protein. Skin grafts generated with keratinocytes carrying the
114-bp deletion allele that encoded an exon 80-lacking (DE80)
variant displayed C7 deposition at the BMZ and dermal-epidermal
adhesion. However, frame restoration by a smaller (1 bp) deletion
that results in substitution of four amino acids within the exon
80-encoded sequence led to retention of the C7 protein in the basal
layer of the epidermis and blister formation in the skin grafts.
This suggests that only variants maintaining the Gly-X-Y pattern
in the C7 triple helix-forming domain are appropriately processed
and secreted by the keratinocytes and ﬁt for anchoring ﬁbrils
formation.
Figure 6. In Vivo Skin Regeneration from Frame-Restored Patient
Keratinocyte Clone 19.C Expressing a C7 Variant Lacking the Exon
80-Encoded Sequence
(A) COL7A1 cDNA and C7 amino acid sequences for WT, c.6527insC, and
DE80 (114-bp deletion) alleles. Amino acid substitutions in c.6527insC are
shown in red. (B) Macroscopic appearance of a representative human skin
(delineated by dotted line) regenerated from clone 19.C. (C) Demonstration of
dermal-epidermal adhesion in patient skin regenerated from clone 19.C.
Firm pulling from the edge of an incision did not cause dermal-epidermal
detachment. (D) H&E staining of regenerated patient skin showing epidermal-
dermal adhesion and normal epidermal architecture. Scale bar, 100 mm.
(E) Immunohistochemical staining using an antibody speciﬁc for human
involucrin to show normal human epidermal differentiation of the gene-corrected
patient skin graft at the mouse (Mo)-human(Hu) skin boundary. Scale bar,
100mm. (F, G, and H) Immunoﬂuorescence staining using an antibody speciﬁc
for human C7 (red). Normal C7 deposition was found along the BMZ of a gene-
corrected patient skin graft regenerated from clone 19.C keratinocytes (F) and in
normal human keratinocyte positive control graft (G). No C7 staining was found
in sections of a negative control graft regenerated from unedited patient 2
keratinocytes (H). Cell nuclei were stained with DAPI (blue). Asterisks denote
blistering between dermis and epidermis. Scale bar, 50 mm. (I) Electron micro-
scopy analysis showed the presence of mature anchoring ﬁbrils (arrowheads) at
the dermal-epidermal junction of gene-corrected patient skin regenerated from
clone 19.C keratinocytes. Scale bar, 200 nm.
www.moleculartherapy.orgOur multiple grafting experiments provide proof of the clinical
potential of clonal gene therapy protocols based on the excision of
exons containing pathogenic mutations. Conceivably, improved
gene editing tools will bring the combined genetic and cellular
approach to a higher feasibility level.
MATERIALS AND METHODS
Culture of Primary RDEB Patient Keratinocytes and
Transduction with Ad-TALENs T6/T7
Patient keratinocytes were originally obtained from skin biopsies
of two RDEB (RDEB-sev gen) patients carrying the c.6527insC
homozygous mutation in the COL7A1 gene.28,34 Clinical features
of these patients have been previously described (patients 4 and 9
in Escámez et al.28). Skin biopsies were obtained from patients after
approval from the Ethics Committee of the collaborating hospital
upon informed consent. Primary human keratinocytes were cultured
as previously described.25 Human primary RDEB keratinocytes
(from patients P1 and P2) were plated onto lethally irradiated
3T3-J2 cells and cultured in keratinocyte growth complete FAD
(cFAD) medium, a DMEM, and Ham’s F12 media mixture (3:1)
containing fetal bovine serum (10%), penicillin-streptomycin (1%),
glutamine (2%), insulin (5 mg/mL), adenine (0.18 mmol/L), hydro-
cortisone (0.4 mg/ml), cholera toxin (0.1 nmol/L), triiodothyronine
(2 nmol/L), epidermal growth factor (EGF) (10 ng/mL), and
Y-27632 ROCK inhibitor (Sigma) at 10 mM. For viral transduction,
cells were trypsinized and infected in suspension with the TALEN-
expressing adenoviral vectors (MOI, 300) in the presence of
polybrene (8 mg/mL) (Sigma, St. Louis, MO). 1  106 transduced
keratinocytes were then plated in a 35-mm dish without feeder layer
in CnT-57 (CellnTec, Bern, Switzerland) medium and cultured at
37C for 24 hr followed by 48 hr at 30C. Cells were then trypsinized
and plated at low density in 100-mm plates (103 cells/plate) with
2 106 lethally irradiated 3T3 feeder cells per plate, to obtain isolated
clones. Cell clones were then collected using polystyrene cloning cyl-
inders (Sigma, St. Louis, MO) and expanded for cryopreservation
and genomic DNA extraction.
Cel I (Surveyor) Analysis
Genomic DNA was isolated by isopropanol precipitation of
keratinocytes lysates (lysis buffer was Tris [pH 8], 100 mM,
EDTA 5 mM, SDS 0.2%, NaCl 200 mM, 1 mg/mL proteinase K
[Roche Diagnostics, Mannheim, Germany]) and resuspended in
Tris/EDTA (TE) buffer. Approximately 100 ng of genomic DNA
were used for PCR ampliﬁcation. PCR fragments spanning the
TALENs’ target sites were generated with primers F1/R. F,:
50-gtgagtggtggctgaagcac-30; R, 50-accccaccaaggaaactga-30. PCR pro-
gram TD 68-63 was as follows: 94C for 3 min, ﬁve cycles of
94C for 30 s, 68C for 30 s, 72C for 45 s, decreasing annealing
temperature 1C every cycle, followed by 30 cycles of 94C for
30 s, 63C for 30 s, 72C for 45 s, then 72C for 7 min. PCR prod-
ucts were subjected to melting and reannealing to yield heterodu-
plex DNA, digested with Surveyor nuclease (IDT, Iowa, IA) at
42C for 1 hr, resolved in 1.5% agarose gels and visualized by
ethidium bromide staining.Molecular Therapy: Nucleic Acids Vol. 11 June 2018 75
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Genomic DNA isolation and PCR ampliﬁcation with primers F1/R
were performed as described above. PCR products were treated with
illustra ExoProStar (GE Healthcare, UK), sequenced using Big Dye
Terminator V.1.1 Cycle Sequencing kit (Thermo Fisher, Waltham,
MA), and examined on a 3730 DNA Analyzer (Life Technologies,
Carlsbad, CA). Chromatograms were analyzed using Sequencher
(Gene Codes, Ann Harbor, MI) and Chromas (Technelysium,
Australia) software.
Off-Target Analysis
Potential off-target sites were predicted using the PROGNOS
software to search the hg19 genome for the TALEN pair targeting
the 50-TGCCCTCTCTATGTAGGGT NN.NN AGGCCCCCCC
TGGCCCA-30, using the following RVDs:
left, 01NN02HD03HD04HD05NG06HD07NG08HD09NG10NI11N
G12NN13NG14NI15NN16NN17NN18NG; right, 01NN02NN03NN
04HD05HD06NI07NN08NN09NN10NN11NN12NN13NN14HD15
HD16NG, allowing up to six mismatches in each nuclease half-site
and spacing distances between 10 to 28 bp. Homodimers and hetero-
dimers of the nucleases were included in the prediction. Predicted
off-target sites (Table S1) were PCR ampliﬁed using speciﬁc primer
pairs (Table S2) and PCR products were analyzed using the Surveyor
kit as described above.
COL7A1 Transcription Analysis by RT-PCR and Real-Time qPCR
Total RNA was extracted from keratinocytes with miRNeasy Mini Kit
(QIAGEN, Hilden, Germany) and complementary DNA (cDNA) was
synthesized using the SuperScript III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA). The following primers were used to
amplify 241 (unedited) and 205 (exon 80 deleted) bp fragments span-
ning exons 78–84 ofCOL7A1: F, 50-AGGGGTCAGGACGGCAAC30
and R, 50- CAGCTCCAGTAGGTCCAGTCAG30. The PCR pro-
gram was as follows: 94C for 3 min, ﬁve cycles of 94C for 30 s,
68C for 30 s, 72C for 45 s, decreasing annealing temperature 1C
every cycle, followed by 25 cycles of 94C for 30 s, 63C for 30 s,
72C for 45 s, then 72C for 7 min. The human glyceraldehyde-3-
phosphate dehydrogenase gene (GAPDH) was analyzed as a loading
control with GAPDH-speciﬁc primers: F, 50-accacagtccatgccatcac-30,
and R, 50-tccaccaccctgttgctgt-30. For the real-time qPCR analysis,
1:20 dilutions of each cDNA synthesis reaction were analyzed in
triplicate using Taqman gene-expression assays Hs00164310_m1
(COL7A1 exon64 probe), Hs01574801_g1 (COL7A1 exon80 probe),
and Hs02758991_g1 (GAPDH probe, control). Ampliﬁcation was per-
formed using a QuantStudio 6 Flex Real-Time PCR System (Applied
Biosystems).
Western Blot Analysis
Keratinocytes were lysed in protein extraction buffer (50 mM Tris-
HCl [pH 7.5], 100 mM NaCl, 1% Nonidet P-40, 4 mM EDTA)
containing proteinase inhibitors cocktail (Complete Mini, EDTA-
free; Roche Diagnostics, Mannheim, Germany). Lysates were
incubated for 30 min on ice and centrifuged at 15,000  g for76 Molecular Therapy: Nucleic Acids Vol. 11 June 201830 min at 4C. Supernatants were collected and protein concentra-
tions were measured using the Bradford assay (BioRad, Hercules,
CA). For each sample, 40 mg of total protein was resolved
on NuPAGE Novex 3%–8% Tris-Acetate gel electrophoresis
(Invitrogen, Carlsbad, CA) and electrotransferred to nitrocellulose
membranes (Invitrogen, Carlsbad, CA). For type VII collagen
analysis, blots were probed with a monospeciﬁc polyclonal anti
C7 antibody (a generous gift from Dr A. Nystrom). Antibodies
against vinculin (Abcam) or a-tubulin (Sigma, St. Louis, MO)
were used as loading controls. Visualization was performed by
incubating with HRP-conjugated anti-rabbit antibody (Amersham,
Burlington, MA) and West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL).
Immunoﬂuorescence and Immunohistochemical Staining
For immunoﬂuorescence detection of C7 in keratinocytes or in
skin graft sections, cells grown on glass coverslips or 7-mm frozen
sections of grafted skin tissue were ﬁxed in methanol/acetone
(1:1) for 10 min at 20C. After washing three times in PBS and
once in PBS with 3% BSA (Sigma Aldrich, St. Louis, MO) for
30 min, cells or cryosections were incubated with monospeciﬁc
polyclonal anti C7 antibody (a generous gift from Dr A. Nystrom)
at 1:5,000 dilution. Secondary antibody (Alexa Fluor 488, Invitro-
gen, Carlsbad, CA) was used at 1:1,000 dilution. After the ﬁnal
washing step in PBS, preparations were mounted using Mowiol
(Hoechst, Somerville, NJ) mounting medium and DAPI 20 mg/m
(Sigma) for nuclei visualization. H&E staining was performed on
parafﬁn-embedded skin samples. Immunoperoxidase staining for
human involucrin was performed using rabbit SY5 monoclonal
antibody (Sigma) using the ABC peroxidase kit (Vector) with
diaminobenzidine as a substrate.
Generation of Skin Equivalents and Grafting onto
Immunodeﬁcient Mice
Keratinocytes were seeded on RDEB-containing ﬁbrin dermal
equivalents prepared as previously described.35 Bioengineered skin
equivalents were grafted onto the back of immunodeﬁcient nu/nu
mice.25 Twelve weeks after grafting, mice were sacriﬁced and grafts
harvested for skin immunoﬂuorescence, immunohistochemical and
histological analysis, and electron microscopy studies. Animal studies
were approved by our institutional animal care and use committee
according to all legal regulations.
Electron Microscopy
Specimens of ca. 0.4  0.3 cm were ﬁxed for at least 2 hr at room
temperature in 3% glutaraldehyde solution in 0.1 M cacodylate buffer
(pH 7.4), cut into pieces of ca. 1 mm3, washed in buffer, postﬁxed for
1 hr at 4C in 1% osmium tetroxide, rinsed in water, dehydrated
through graded ethanol solutions, transferred into propylene oxide,
and embedded in epoxy resin (glycidether 100). Semithin and
ultrathin sections were cut with an ultramicrotome (Reichert
Ultracut E). Ultrathin sections were treated with uranyl acetate and
lead citrate and examined with an electron microscope (JEM 1400)
equipped with a 2k CCD camera (TVIPS).
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Supplementary Figure S2. Clone 19n  genotype. Sanger sequencing  chromatogram of C7-negative clone 19n 
revealed the presence of overlapping chromatograms for the c.6527insC (unmodified, upper nucleotide 
sequence) and c.6503_6511del9 (9 bp deletion, lower nucleotide sequence) alleles.  
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Supplementary Figure S4. Histological (H&E staining) analysis of a human skin graft regenerated from clone 
11, expressing a C7 variant with a 4 aminoacids substitution. Consistent with the inability to promote 
epidermal-dermal attachment by this C7 variant, the epidermis separated from the dermis (not seen in the 
picture) during sample processing. Otherwise, basal cells of the epidermis and epidermal differentiation appear 
normal, suggesting that intracellular accumulation of C7 is not cytotoxic. Scale bar: 100 µm 
Supplementary Figure S5. Immunofluorescence detection of C7 (red) on a section of a skin graft generated 
with mixed clone 19 keratinocytes. C7 deposition along the BMZ coincided with areas showing dermal-
epidermal attachment. Blistering spots (asterisks) matched areas negative for C7, likely originating from 
uncorrected epidermal stem cells. Cell nuclei were stained with DAPI (blue). Scale bar: 50µm.  
genomic number of 
chromosome gene region Match type target sequence F target sequence R mismatches
 Chr3 COL7A1 exon 80 L14R TGCCCTCTCTATGTAGGGT TGGGCCAGGGGGGGCCT 0
 Chr3 COL7A1 exon 36 R10R TGGaCCActGGGGGaCc gaaGCCctGGGGGGCCa 11
 Chr3 COL7A1 exon 56 R25R gGGaCCtGaGGGctCCT gGGtCCtGGGGGacCCT 12
 Chr3 COL7A1 exon 58 R17R TGccaCAGGGaGaGCCT TGGGCCctcGaGGaCCc 11
 Chr3 COL7A1 exon 67 R19R TtGGaCcccaGGGGCCT ctGGCCAGGaGGGcCCa 11
 Chr3 COL7A1 intron 112 R21R TGGGCCtGGGaGGGCCT TGaGggAGGtaGGGCCc 8
 Chr3 COL7A1 intron 112 R10R aGGGCCtGGGtGGGCCT TGaGggAGGtaGGGCCc 9
 Chr3 UT-COL7A1 5´-UTR R27R TGctCCAGGtGGGGggc AGGCagCCCCTtcCCCc 11
 Chr19 NFIX intron R22R cGGtggAGGcGGGGCCT TGGGCCcGGGGGGGCCT 6
 Chr1 PROX1 intron R17R caGGggAGGGGaGGCCT TGGGCCAtGGGaGGCCT 7
 Chr10 LOC100130539 intergenic R24R TaGcCaAGGGaaGcCCT TGGGCCAGaaGGcaCCT 10
 Chr3 LRIG1 intron R16R TGGGCCcGGGGaGGCCT TGGGgaAGGGGaGcCCc 7
 Chr1 ARHGEF19 intron R12R TGGGCagGGcaGGGGCT gGGtCCAGGGGGGGCCT 7
 Chr20 GDF5 exon R17R caGGCCAGGattGGCCa cGGGCCAGGGGGGGCCT 7
 Chr11 MOB2 intron R24R TGGGCCAGGGGGGcCCT ctGGCCAGtcGGGaCCa 7
 Chr3 FAMD3 intron R28R TaGaCCAGGGaGGGCCc TGGGCCAGGctacaCCT 9
 Chr22 LOC100128946 intergenic R13R caGcCCAGGGGGaGCCT TGGGCCcGGGGaaGCCT 7
 Chr3 LRRC3B intergenic R17R TGGGCCAGGGaGaGCCT TGacCatGGGaGGGCCc 8
 Chr12 TPCN1 intron R11R TGGGgCAGGaGGGGCCT TGGGagAGGaGGaGCCT 6
 Chr19 TBCB intron R20R TGaGCtAGGaGGGcCCT TcaGCCAGaGGGaGCCT 8
 Chr17 RBFOX3 intron R23R TGGaCCAGGGcctGCCT TGcGCCAGaaGaGGCCT 8
Supplementary Table 1. Potential off target sites predicted by PROGNOS software. Nucleotides 
mismatching TALENs-binding consensus sequences are shown in red.  
Supplementary Table 2. List of primers used for PCR amplification of potential off-target sites. 
Gene Forward primer Reverse primer Length (bp)
COL7A1 ex80 GTGAGTGGTGGCTGAAGCAC ACCCCACCAAGGAAACTGA 494
COL7A1ex34-36 CCCAGGGTTCTTCCACAGG CATGGTGAGGATGGGGGTAA 693
COL7A1ex54-56 GGAGGCATGGGGTGATGG CCCAAGTTCCCCGAAGCA 643
COL7A1ex56-60 GATCCCTGGAGCCCCTC CACCCTGTGGAAAATAGAGTGGTAA 633
COL7A1ex65-67 CACAGGCCATGCTCCAAGA GGCAGAACACAAAGGGGTCA 603
COL7A1EX111-112 AGCTCTGACTCCTGATCCCT GGGACTATGGTGAGACTGCA 508
UT-COL7A1 GCTGGAGGCAGTGAAGACCA TCCCAGCACCCTTTGAGAGA 452
NFIX CTAGGCTTGAGTGTCTGATGTGTG CAACTCCAATGGGGGAAGCC 357
PROX1 AGATGGGTGCAAACCTCACCTTC ATTTGGGCACAGGCGTCTGG 331
LOC100130539 CTGTCTCGATTGCGATCCAGG TGGTTAGACAATGGGTGCAGCC 325
LRIG1 TTCCAGGGAATGGGGGAAAGTG GGGAAAAACAGTGGTTATCAGCATGCATAG 357
ARHGEF19 GAGTTCCTCTGTCCTCTTCATGG ATTGTGCTGATCCCACCTTCCAGA 326
GDF5 CTGTGTCAGGCCTCCTGTCT CCAAACCAGAGGCACCTTTGCT 330
MOB2 AGAAGTGACCACTGGCAGGG CTGGAAGCCACCTAGCAAGC 345
FAM3D CTTTGGAGCAAAGCTGCAGGC GAAGGGGCACCTTTACCTACTC 343
LOC100128946 CTCCCTGAGCGGGTGCTTTT TGATGACGATGGCAGGGGCT 344
LRRC3B CTCATCTCTGCAGCTATCTGCTC TGCTCCCATCTCCAAGCAGG 326
TPCN1 AGGGGAGAGCTGTTTTGGGC AATCAAAGAGAACACGTGGCCGG 326
TBCB AGACACCTCAGGGTGTTCCTTG CAGCCTCCCAATGTACTGGGT 325
RBFOX3 AGTTCACCAGCCCTACGCAG GCTTTGGGCTTTGCCAAGGG 327
